{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:56:44Z","timestamp":1790621804814,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13014-019-1360-7","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T18:09:38Z","timestamp":1567447778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9619-1427","authenticated-orcid":false,"given":"S.","family":"Lautenschlaeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Iancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Flatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thiemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dumke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hauswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vordermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mauz-K\u00f6rholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Engenhart-Cabillic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Eberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,2]]},"reference":[{"key":"1360_CR1","volume-title":"Krebs in Deutschland |","author":"R Koch-Institut","year":"2013","unstructured":"Koch-Institut R. Krebs in Deutschland |; 2013\/2014."},{"key":"1360_CR2","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1200\/JCO.2001.19.11.2905","volume":"19","author":"E D\u00fchmke","year":"2001","unstructured":"D\u00fchmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol. 2001;19:2905\u201314. \n                    https:\/\/doi.org\/10.1200\/JCO.2001.19.11.2905\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/annonc\/mdh046","volume":"15","author":"M Sieber","year":"2004","unstructured":"Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin's disease with COPP\/ABV\/IMEP versus COPP\/ABVD and consolidating radiotherapy: final results of the German Hodgkin's lymphoma study group HD6 trial. Ann Oncol. 2004;15:276\u201382.","journal-title":"Ann Oncol"},{"key":"1360_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1200\/JCO.2002.20.2.476","volume":"20","author":"M Sieber","year":"2002","unstructured":"Sieber M, Tesch H, Pfistner B, et al. Rapidly alternating COPP\/ABV\/IMEP is not superior to conventional alternating COPP\/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's lymphoma study group trial HD5. J Clin Oncol. 2002;20:476\u201384. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.20.2.476\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR5","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","volume":"25","author":"A Engert","year":"2007","unstructured":"Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25:3495\u2013502. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.07.0482\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR6","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's lymphoma study group. J Clin Oncol. 2003;21:3601\u20138. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.03.023\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR7","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa022473","volume":"348","author":"V Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386\u201395. \n                    https:\/\/doi.org\/10.1056\/NEJMoa022473\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1360_CR8","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","volume":"28","author":"HT Eich","year":"2010","unstructured":"Eich HT, Diehl V, G\u00f6rgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD11 trial. J Clin Oncol. 2010;28:4199\u2013206. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.29.8018\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640\u201352. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1000067\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1360_CR10","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"P Borchmann","year":"2011","unstructured":"Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin study group. J Clin Oncol. 2011;29:4234\u201342. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.33.9549\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR11","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385:1418\u201327. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61469-0\n                    \n                  .","journal-title":"Lancet"},{"key":"1360_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","volume":"30","author":"B von Tresckow","year":"2012","unstructured":"von Tresckow B, Pl\u00fctschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012;30:907\u201313. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.5807\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR13","unstructured":"Engert A. HD17 for Intermediate Stage Hodgkin Lymphoma. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01356680\n                    \n                  ."},{"key":"1360_CR14","unstructured":"Engert A. HD16 for Early Stage Hodgkin Lymphoma (HD16). NCT00736320. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00736320\n                    \n                  ."},{"key":"1360_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1055\/s-2008-1046611","volume":"206","author":"G Schellong","year":"1994","unstructured":"Schellong G, H\u00f6rnig-Franz I, Rath B, et al. Reduzierung der Strahlendosen auf 20-30 Gy im Rahmen einer kombinierten Chemo\u2212\/Radiotherapie beim Morbus Hodgkin im Kindesalter. Ein Bericht der kooperativen Therapiestudie DAL-HD-87. Klin Padiatr. 1994;206:253\u201362. \n                    https:\/\/doi.org\/10.1055\/s-2008-1046611\n                    \n                  .","journal-title":"Klin Padiatr"},{"key":"1360_CR16","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.1999.17.12.3736","volume":"17","author":"G Schellong","year":"1999","unstructured":"Schellong G, P\u00f6tter R, Br\u00e4mswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian pediatric Hodgkin's disease study group. J Clin Oncol. 1999;17:3736\u201344. \n                    https:\/\/doi.org\/10.1200\/JCO.1999.17.12.3736\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-2008-1026870","volume":"198","author":"G Schellong","year":"1986","unstructured":"Schellong G, Br\u00e4mswig J, Ludwig R, et al. Kombinierte Behandlungsstrategie bei \u00fcber 200 Kindern mit Morbus Hodgkin: Abgestufte Chemotherapie, Involved-Field-Bestrahlung mit erniedrigten Dosen und selektive Splenektomie. Ein Bericht der kooperativen Therapiestudie DAL-HD-82. Klin Padiatr. 1986;198:137\u201346. \n                    https:\/\/doi.org\/10.1055\/s-2008-1026870\n                    \n                  .","journal-title":"Klin Padiatr"},{"key":"1360_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/s-2008-1033710","volume":"200","author":"G Schellong","year":"1988","unstructured":"Schellong G, H\u00f6rnig I, Br\u00e4mswig J, et al. Zur Bedeutung des procarbazins in der Chemo therapie des Morbus Hodgkin--Ein Bericht der Kooperativen Therapiestudie DAL-HD-85. Klin Padiatr. 1988;200:205\u201313. \n                    https:\/\/doi.org\/10.1055\/s-2008-1033710\n                    \n                  .","journal-title":"Klin Padiatr"},{"key":"1360_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0950-3536(96)80030-8","volume":"9","author":"G Schellong","year":"1996","unstructured":"Schellong G. 11 treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric study group. Bailli\u00e8re's Clin Haematol. 1996;9:619\u201334. \n                    https:\/\/doi.org\/10.1016\/S0950-3536(96)80030-8\n                    \n                  .","journal-title":"Bailli\u00e8re's Clin Haematol"},{"key":"1360_CR20","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","volume":"28","author":"C Mauz-K\u00f6rholz","year":"2010","unstructured":"Mauz-K\u00f6rholz C, Hasenclever D, D\u00f6rffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680\u20136. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.26.9381\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR21","unstructured":"K\u00f6rholz D. First international inter-group study for classical Hodgkin\u2019s lymphoma in children and adolescents - EuroNet-PHL-C1 -. EuroNet-Paediatric Hodgkin\u2019s Lymphoma Group."},{"key":"1360_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007\u201317. \n                    https:\/\/doi.org\/10.1001\/jamainternmed.2015.1180\n                    \n                  .","journal-title":"JAMA Intern Med"},{"key":"1360_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/pbc.22664","volume":"55","author":"G Schellong","year":"2010","unstructured":"Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145\u201352. \n                    https:\/\/doi.org\/10.1002\/pbc.22664\n                    \n                  .","journal-title":"Pediatr Blood Cancer"},{"key":"1360_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM199603213341201","volume":"334","author":"S Bhatia","year":"1996","unstructured":"Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745\u201351. \n                    https:\/\/doi.org\/10.1056\/NEJM199603213341201\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1360_CR25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second Cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373:2499\u2013511. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1505949\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1360_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.290.4.465","volume":"290","author":"LB Travis","year":"2003","unstructured":"Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465\u201375. \n                    https:\/\/doi.org\/10.1001\/jama.290.4.465\n                    \n                  .","journal-title":"JAMA"},{"key":"1360_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","volume":"94","author":"LB Travis","year":"2002","unstructured":"Travis LB. Lung Cancer following chemotherapy and radiotherapy for Hodgkin's disease. Cancer Spectr Knowl Environ. 2002;94:182\u201392. \n                    https:\/\/doi.org\/10.1093\/jnci\/94.3.182\n                    \n                  .","journal-title":"Cancer Spectr Knowl Environ"},{"key":"1360_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1097-0142(19840115)53:2<232::AID-CNCR2820530208>3.0.CO;2-F","volume":"53","author":"EC Halperin","year":"1984","unstructured":"Halperin EC, Greenberg MS, Suit HD. Sarcoma of bone and soft tissue following treatment of Hodgkin's disease. Cancer. 1984;53:232\u20136. \n                    https:\/\/doi.org\/10.1002\/1097-0142(19840115)53:2<232::AID-CNCR2820530208>3.0.CO;2-F\n                    \n                  .","journal-title":"Cancer"},{"key":"1360_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijrobp.2011.11.022","volume":"84","author":"P Rajaraman","year":"2012","unstructured":"Henderson TO, Rajaraman P, Stovall M, et al. Risk Factors Associated With Secondary Sarcomas in Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study. Int J Radiat Oncol *Biol*Phys. 2012;84:224\u201330. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2011.11.022\n                    \n                  .","journal-title":"Int J Radiat Oncol *Biol*Phys"},{"key":"1360_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/jnci\/djk052","volume":"99","author":"J Whitton","year":"2007","unstructured":"Henderson TO, Whitton J, Stovall M, et al. Secondary sarcomas in childhood Cancer survivors: a report from the childhood Cancer survivor study. J Natl Cancer Inst. 2007;99:300\u20138. \n                    https:\/\/doi.org\/10.1093\/jnci\/djk052\n                    \n                  .","journal-title":"J Natl Cancer Inst"},{"key":"1360_CR31","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1200\/JCO.2003.11.059","volume":"21","author":"S Bhatia","year":"2003","unstructured":"Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the late effects study group. J Clin Oncol. 2003;21:4386\u201394. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.11.059\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR32","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/S0140-6736(05)66695-0","volume":"365","author":"AJ Sigurdson","year":"2005","unstructured":"Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the childhood Cancer survivor study): a nested case-control study. Lancet. 2005;365:2014\u201323. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)66695-0\n                    \n                  .","journal-title":"Lancet"},{"key":"1360_CR33","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1210\/jcem.85.9.6808","volume":"85","author":"C Sklar","year":"2000","unstructured":"Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the childhood Cancer survivor study. J Clin Endocrinol Metab. 2000;85:3227\u201332. \n                    https:\/\/doi.org\/10.1210\/jcem.85.9.6808\n                    \n                  .","journal-title":"J Clin Endocrinol Metab"},{"key":"1360_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","volume":"17","author":"N Bhakta","year":"2016","unstructured":"Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude lifetime cohort study. Lancet Oncol. 2016;17:1325\u201334. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30215-7\n                    \n                  .","journal-title":"Lancet Oncol"},{"key":"1360_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","volume":"92","author":"AR Filippi","year":"2015","unstructured":"Filippi AR, Ragona R, Piva C, et al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk. Int J Radiat Oncol Biol Phys. 2015;92:161\u20138. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.030\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1360_CR36","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10147-015-0863-y","volume":"20","author":"L Specht","year":"2015","unstructured":"Specht L, Yahalom J. The concept and evolution of involved site radiation therapy for lymphoma. Int J Clin Oncol. 2015;20:849\u201354. \n                    https:\/\/doi.org\/10.1007\/s10147-015-0863-y\n                    \n                  .","journal-title":"Int J Clin Oncol"},{"key":"1360_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","volume":"84","author":"BS Hoppe","year":"2012","unstructured":"Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84:449\u201355. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.034\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1360_CR38","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ijrobp.2011.06.1959","volume":"83","author":"BS Hoppe","year":"2012","unstructured":"Hoppe BS, Flampouri S, Su Z, et al. Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys. 2012;83:260\u20137. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2011.06.1959\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1360_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahalom","year":"2015","unstructured":"Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92:11\u201331. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.009\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1360_CR40","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","volume":"28","author":"BS Hoppe","year":"2017","unstructured":"Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol. 2017;28:2179\u201384. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx287\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"1360_CR41","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1080\/0284186X.2016.1197422","volume":"55","author":"BS Hoppe","year":"2016","unstructured":"Hoppe BS, Tsai H, Larson G, et al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. Acta Oncol (Stockholm, Sweden). 2016;55:1378\u201380. \n                    https:\/\/doi.org\/10.1080\/0284186X.2016.1197422\n                    \n                  .","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"key":"1360_CR42","doi-asserted-by":"publisher","unstructured":"Everett AS, Hoppe BS, Louis D, et al. Comparison of techniques for involved-site radiation therapy in patients with lower mediastinal lymphoma. Pract Radiat Oncol. 2019. \n                    https:\/\/doi.org\/10.1016\/j.prro.2019.05.009\n                    \n                  .","DOI":"10.1016\/j.prro.2019.05.009"},{"key":"1360_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.prro.2019.01.006","volume":"9","author":"G Ntentas","year":"2019","unstructured":"Ntentas G, Dedeckova K, Andrlik M, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the Most? Pract Radiat Oncol. 2019;9:179\u201387. \n                    https:\/\/doi.org\/10.1016\/j.prro.2019.01.006\n                    \n                  .","journal-title":"Pract Radiat Oncol"},{"key":"1360_CR44","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/pbc.26044","volume":"63","author":"J Wray","year":"2016","unstructured":"Wray J, Flampouri S, Slayton W, et al. Proton therapy for pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2016;63:1522\u20136. \n                    https:\/\/doi.org\/10.1002\/pbc.26044\n                    \n                  .","journal-title":"Pediatr Blood Cancer"},{"key":"1360_CR45","unstructured":"Mauz-K\u00f6rholz C. Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents - EuroNet-PHL-C2. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684708\n                    \n                  ."},{"key":"1360_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.radonc.2019.05.009","volume":"138","author":"M Levis","year":"2019","unstructured":"Levis M, Filippi AR, Fiandra C, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients. Radiother Oncol. 2019;138:52\u20138. \n                    https:\/\/doi.org\/10.1016\/j.radonc.2019.05.009\n                    \n                  .","journal-title":"Radiother Oncol"},{"key":"1360_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1748-717X-7-186","volume":"7","author":"C Fiandra","year":"2012","unstructured":"Fiandra C, Filippi AR, Catuzzo P, et al. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin\u2019s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol. 2012;7:186. \n                    https:\/\/doi.org\/10.1186\/1748-717X-7-186\n                    \n                  .","journal-title":"Radiat Oncol"},{"issue":"15","key":"1360_CR48","doi-asserted-by":"publisher","first-page":"155005","DOI":"10.1088\/1361-6560\/ab2611","volume":"64","author":"V Flatten","year":"2019","unstructured":"Flatten V, Baumann K-S, Weber U, Engenhart-Cabillic R, Zink K. Quantification of the dependencies of the Bragg peak degradation due to lung tissue in proton therapy on a CT-based lung tumor phantom. Phys Med Biol. 2019;64(15):155005.","journal-title":"Phys Med Biol"},{"key":"1360_CR49","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1088\/0031-9155\/55\/17\/014","volume":"55","author":"SM Zenklusen","year":"2010","unstructured":"Zenklusen SM, Pedroni E, Meer D. A study on repainting strategies for treating moderately moving targets with proton pencil beam scanning at the new gantry 2 at PSI. Phys Med Biol. 2010;55:5103\u201321. \n                    https:\/\/doi.org\/10.1088\/0031-9155\/55\/17\/014\n                    \n                  .","journal-title":"Phys Med Biol"},{"key":"1360_CR50","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging. 2012;30:1323\u201341. \n                    https:\/\/doi.org\/10.1016\/j.mri.2012.05.001\n                    \n                  .","journal-title":"Magn Reson Imaging"},{"key":"1360_CR51","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.canrad.2011.04.003","volume":"15","author":"V Gr\u00e9goire","year":"2011","unstructured":"Gr\u00e9goire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2011;15:555\u20139. \n                    https:\/\/doi.org\/10.1016\/j.canrad.2011.04.003\n                    \n                  .","journal-title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique"},{"key":"1360_CR52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","volume":"34","author":"FA van Nimwegen","year":"2016","unstructured":"van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34:235\u201343. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.63.4444\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR53","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987\u201398. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1209825\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1360_CR54","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","volume":"2","author":"MV Maraldo","year":"2015","unstructured":"Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015;2:e492\u2013502. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(15)00153-2\n                    \n                  .","journal-title":"Lancet Haematol"},{"key":"1360_CR55","doi-asserted-by":"publisher","unstructured":"Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv008\n                    \n                  .","DOI":"10.1093\/jnci\/djv008"},{"key":"1360_CR56","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J","volume":"53","author":"LS Constine","year":"1984","unstructured":"Constine LS, Donaldson SS, McDougall IR, Cox RS, Link MP, Kaplan HS. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer. 1984;53:878\u201383. \n                    https:\/\/doi.org\/10.1002\/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J\n                    \n                  .","journal-title":"Cancer"},{"key":"1360_CR57","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.ijrobp.2010.09.054","volume":"82","author":"L Cella","year":"2012","unstructured":"Cella L, Conson M, Caterino M, et al. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2012;82:1802\u20138. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.054\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1360_CR58","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1200\/JCO.2008.20.7738","volume":"27","author":"PD Inskip","year":"2009","unstructured":"Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009;27:3901\u20137. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.20.7738\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jnci\/85.1.25","volume":"85","author":"SL Hancock","year":"1993","unstructured":"Hancock SL, Tucker MA, Hoppe RT. Breast Cancer after treatment of Hodgkin's disease. JNCI Journal of the National Cancer Institute. 1993;85:25\u201331. \n                    https:\/\/doi.org\/10.1093\/jnci\/85.1.25\n                    \n                  .","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"1360_CR60","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ijrobp.2015.11.046","volume":"94","author":"PD Inskip","year":"2016","unstructured":"Inskip PD, Sigurdson AJ, Veiga L, et al. Radiation-related new primary solid cancers in the childhood Cancer survivor study: comparative radiation dose response and modification of treatment effects. Int J Radiat Oncol Biol Phys. 2016;94:800\u20137. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2015.11.046\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1360_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3238\/arztebl.2014.0003","volume":"111","author":"G Schellong","year":"2014","unstructured":"Schellong G, Riepenhausen M, Ehlert K, et al. Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up. Deutsches Arzteblatt international. 2014;111:3\u20139. \n                    https:\/\/doi.org\/10.3238\/arztebl.2014.0003\n                    \n                  .","journal-title":"Deutsches Arzteblatt international"},{"key":"1360_CR62","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","volume":"32","author":"CS Moskowitz","year":"2014","unstructured":"Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217\u201323. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.54.4601\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR63","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1200\/JCO.2001.19.6.1610","volume":"19","author":"AJ Swerdlow","year":"2001","unstructured":"Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol. 2001;19:1610\u20138. \n                    https:\/\/doi.org\/10.1200\/JCO.2001.19.6.1610\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR64","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/jnci\/86.13.983","volume":"86","author":"PD Inskip","year":"1994","unstructured":"Inskip PD, Stovall M, Flannery JT. Lung Cancer risk and radiation dose among women treated for breast Cancer. J Natl Cancer Inst. 1994;86:983\u20138. \n                    https:\/\/doi.org\/10.1093\/jnci\/86.13.983\n                    \n                  .","journal-title":"J Natl Cancer Inst"},{"key":"1360_CR65","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2307\/3579003","volume":"141","author":"E Ron","year":"1995","unstructured":"Ron E, Lubin JH, Shore RE, et al. Thyroid Cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141:259. \n                    https:\/\/doi.org\/10.2307\/3579003\n                    \n                  .","journal-title":"Radiat Res"},{"key":"1360_CR66","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"FA van Nimwegen","year":"2017","unstructured":"van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129:2257\u201365. \n                    https:\/\/doi.org\/10.1182\/blood-2016-09-740332\n                    \n                  .","journal-title":"Blood"},{"issue":"Suppl 5","key":"1360_CR67","doi-asserted-by":"publisher","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","volume":"21","author":"D Bovelli","year":"2010","unstructured":"Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl 5):v277\u201382. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdq200\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"1360_CR68","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/10428190500063229","volume":"46","author":"A Avil\u00e9s","year":"2005","unstructured":"Avil\u00e9s A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma. 2005;46:1023\u20138. \n                    https:\/\/doi.org\/10.1080\/10428190500063229\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"key":"1360_CR69","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791\u20139. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)61940-5\n                    \n                  .","journal-title":"Lancet"},{"key":"1360_CR70","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","volume":"24","author":"NY Mudie","year":"2006","unstructured":"Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study. J Clin Oncol. 2006;24:1568\u201374. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.04.2200\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1360_CR71","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.ijrobp.2016.08.018","volume":"96","author":"Z Abou Yehia","year":"2016","unstructured":"Abou Yehia Z, Mikhaeel GN, Smith G, et al. Does bleomycin lung toxicity increase the risk of radiation pneumonitis in Hodgkin lymphoma? Int J Radiat Oncol Biol Phys. 2016;96:951\u20138. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2016.08.018\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1360_CR72","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","volume":"132","author":"BS Dabaja","year":"2018","unstructured":"Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group guidelines. Blood. 2018;132:1635\u201346. \n                    https:\/\/doi.org\/10.1182\/blood-2018-03-837633\n                    \n                  .","journal-title":"Blood"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1360-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1360-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1360-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T23:26:10Z","timestamp":1598916370000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1360-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,2]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1360-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,2]]},"assertion":[{"value":"17 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study has been approved by the local ethics committee. Wherever necessary informed consent from the patients has been obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}